Trial Profile

A Randomized, Double-Masked, Dose-Ranging Study to Evaluate the Safety and Tolerability of TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dazdotuftide (Primary)
Indications Anterior uveitis
Focus Adverse reactions; Proof of concept
Sponsors Tarsier Pharma; Tarsius Pharma

Most Recent Events

02 Dec 2021 According to a Tarsier Pharma media release, data will be presented at the International Ocular Inflammation Society (IOIS) Congress 2021.
17 Dec 2020 Results presented in a Tarsius Pharma media release.
05 Oct 2020 Status changed from active, no longer recruiting to completed, according to a Tarsius Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com